Compare Live Nation Entertainment, Inc. (LYV) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs GeneDx Holdings Corp — how do they compare? Live Nation Entertainment, Inc. trades at $172.16 (market cap $39.92B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Live Nation Entertainment, Inc. is far larger — about 19.8× GeneDx Holdings Corp's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and GeneDx Holdings Corp for 19 Days on average.
| LYV | WGS | |
|---|---|---|
Market Cap | $39.92B | $2.02B |
Volume | 1,982,609 | 734,640 |
Sector | Media | Health |
52-Week High | $188.46 | $167.51 |
52-Week Low | $125.61 | $34.51 |
Typical Hold Time | 72 Days | 19 Days |
Enterprise Value | $42.13B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYV trades at $170.33, down 0.3% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $25.20B in 2025, with net income of $496M, though margins remain thin at 1.96%. Recent news highlights strong fan demand and strategic partnerships, such as the Salesforce Agentforce expansion announced September 16, 2026. Analyst consensus is strongly bullish with a $208.18 price target, supported by 40 buy ratings.
The outlook for LYV is positive due to robust demand for live events and double-digit growth in deferred revenue, but risks include high valuation multiples, legal uncertainties from past DOJ scrutiny, and cost pressures. Earnings volatility is a concern after recent misses, though Q2 2026 beat expectations. Investors should weigh strong institutional support against execution risks in a competitive market.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
